Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients

American Journal of Medicine

Volumn 114, Issue 2, 2003, Pages 135-141

  Curtis, Lesley H ^a   Østbye, Truls ^a   Sendersky, Veronica ^a   Hutchison, Steve ^b   LaPointe, Nancy M Allen ^a   Al Khatib, Sana M ^a   Yasuda, Sally Usdin ^c   Dans, Peter E ^d   Wright, Alan ^d   Califf, Robert M ^a   Woosley, Raymond L ^e   Schulman, Kevin A ^a,f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b AdvancePCS   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d AdvancePCS Clinical Services   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BEPRIDIL; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; CLEMASTINE; DESIPRAMINE; DISOPYRAMIDE; DOFETILIDE; DOXEPIN; ERYTHROMYCIN; FLUOXETINE; IMIPRAMINE; INDAPAMIDE; LEVOFLOXACIN; NEUROLEPTIC AGENT; RISPERIDONE; SALMETEROL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TAMOXIFEN; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; HUMAN; MALE; METABOLIC CLEARANCE RATE; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR; TORSADE DES POINTES;

ADULT; AGED; AMITRIPTYLINE; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLARITHROMYCIN; COHORT STUDIES; DRUG SYNERGISM; ERYTHROMYCIN; FEMALE; FLUOXETINE; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OUTPATIENTS; POLYPHARMACY; PRESCRIPTIONS, DRUG; TORSADES DE POINTES; UNITED STATES;

EID: 0037317605     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01455-9     Document Type: Article

References (33)

1. Hohnloser S.H. Proarrhythmia with class III antiarrhythmic drugs types, risks, and management. Am J Cardiol. 80:1997;82G-89G.
2. Yap Y.G., Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ. 320:2000;1158-1159.
3. Haverkamp W., Breithardt G., Camm A.J., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 47:2000;219-233.
4. Faber T.S., Zehender M., Just H. Drug-induced torsades de pointes. Incidence, management and prevention. Drug Saf. 11:1994;463-476.
5. De Ponti F., Poluzzi E., Montanaro N. QT-interval prolongation by non-cardiac drugs lessons to be learned from recent experience. Eur J Clin Pharmacol. 56:2000;1-18.
6. Roden D.M. A practical approach to torsades de pointes. Clin Cardiol. 20:1997;285-290.
7. Ben-David J., Zipes D.P. Torsades de pointes and proarrhythmia. Lancet. 341:1993;1578-1582.
8. Tan H.L., Hou C.J., Lauer M.R., Sung R.J. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med. 122:1995;701-714.
9. Tatro D.S. Drug Interaction Facts. 1999;Facts and Comparisons, St. Louis, MO.
10. Hohnloser S.H., Woosley R.L. Sotalol. N Engl J Med. 331:1994;31-38.
11. Ebert S.N., Liu X.K., Woosley R.L. Female gender as a risk factor for drug-induced cardiac arrhythmias evaluation of clinical and experimental evidence. J Womens Health. 7:1998;547-557.
12. Lenz T.L., Hilleman D.E. Dofetilide, a new class III antiarrhythmic agent. Pharmacotherapy. 20:2000;776-786.
13. Moss A.J. The QT interval and torsades de pointes. Drug Saf. 21:1999;5-10.
14. Davies A.J., Harindra V., McEwan A., Ghose R.R. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ. 298:1989;325.
15. Tanaka E. Clinically important pharmacokinetic drug-drug interactions role of cytochrome P450 enzymes. J Clin Pharm Ther. 23:1998;403-416.
16. Lin J.H., Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 35:1998;361-390.
17. Bednar M.M., Harrigan E.P., Anziano R.J., et al. The QT interval. Prog Cardiovasc Dis. 43:(5 pt 2):2001;1-45.
18. Hansten P.D., Horn C.J. Drug Interactions Analysis and Management A Clinical Perspective and Analysis of Current Developments. 1999;Facts and Comparisons, St. Louis, MO.
19. Micromedex Heathcare Series [database online]. 2001;Micromedex, Greenwood Village, CO. Edition expires December 2001.
20. Georgetown Center for Education and Research on Therapeutics Web site. International Registry for Drug-Induced Arrhythmias. Available at: http://www.torsades.org. Accessed November 13, 2001.
21. Physicians' Desk Reference. 53rd ed. 1999;Medical Economics, Montvale, NJ.
22. Varriale P. Fluoxetine (Prozac) as a cause of QT prolongation. Arch Intern Med. 161:2001;612.
23. Pacher P., Ungvari Z., Nanasi P.P., et al. Speculations on the difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 6:1999;469-480.
24. Lasser K.E., Allen P.D., Woolhandler S.J., et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 287:2002;2215-2220.
25. Lee P.Y., Alexander K.P., Hammill B.G., et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 286:2001;708-713.
26. Mann R.D. Prescription-event monitoring-recent progress and future horizons. Br J Pharmacol. 46:1998;195-201.
27. Mantel-Teeuwisse A.K., Klungel O.H., Verschuren W.M.M., et al. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol. 54:2001;1181-1186.
28. Strom B.L. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf. 10:2001;389-392.
29. West S.L., Strom B.L. Validity of pharmacoepidemiology drug and diagnosis data. Strom B.L. Pharmacoepidemiology. 3rd ed. 2000;661-705 John Wiley, Sussex, UK.
30. Michalets E.L., Williams C.R. Drug interactions with cisapride clinical implications. Clin Pharmacokinet. 39:2000;49-75.
31. Libersa C.C., Brique S.A., Motte K.B., et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol. 49:2000;373-378.
32. Honig P.K., Wortham D.C., Lazarev A., Cantilena L.R. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol. 36:1996;345-351.
33. Poisal J., Murray L., Chulis G., Cooper B. Prescription drug coverage and spending for Medicare beneficiaries. Health Care Financ Rev. 20:1999;15-26.